Antibiotics Treatment of Cholangitis Post-Kasai Portoenterostomy

• Status: Not yet recruiting
• Trial end date: 2023-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Application of multi-center, prospective study on the severity of postoperative cholangitis biliary atresia classification, according to the degree of cholangitis targeted therapy, to improve the therapeutic effect of postoperative cholangitis biliary atresia, decrease the overuse of antibiotics related complications.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tongji Hospital
• Collaborator: Shanghai Children's Hospital
• Treatments: Meropenem; Sulperazone; Teicoplanin; Tinidazole

Criteria

Inclusion Criteria:

1. Age 3 months to 2 years old, gender is not limited.

2. Patients with cholangitis post-kasai Portoenterostomy.

3. No other treatment before entering the group.

4. The patient must sign an informed consent form and can actively cooperate with the treatment and follow-up.

Exclusion Criteria:

1. Patients with other infectious lesions.

2. Patients with other severe deformity.

3. Patients with end-stage liver failure.

4. Patientsn with liver transplantation.

5. Patients with mental symptoms or other disease.